Bora Q2 2026 slides show strong rebound, revenue miss weighs

On August 13, Bora Pharmaceuticals released its Q2 2026 financial results, displaying a remarkable recovery with earnings growth tripling, although the company underperformed revenue forecasts. Investors reacted negatively, pushing Bora's shares down 3.08% to $409. The presentation demonstrated the company's evolution from a generics-focused manufacturer to a diversified pharmaceutical entity with expanding specialty drug, CDMO, and consumer healthcare divisions.

CEO Bobby Sheng highlighted the company's rebound from a planned quarter one slowdown, citing maintenance and supply chain challenges. Despite a 58% revenue shortfall, Bora's adjusted earnings per share reached $5.34, surpassing the forecasted $4.79 by 11.5%. Revenue of $2.3 billion significantly fell short of the estimated $5.48 billion.

Q2 2026 results showed robust sequential improvements across vital metrics, with revenue hitting NT$5,889 million, a 47% increase from Q1 and 21% year-over-year growth. The business mix shifted, with CDMO accounting for 36% of revenue, pharma sales at 50%, and consumer healthcare at 14%. Revenue from CDMO surged 40.2% sequentially and 33% year-over-year, while pharma sales grew by 30.4%.

Consumer Healthcare showed explosive growth of 234% year-over-year and 354% sequentially. Bora's cash position improved to NT$8,431 million, up from NT$4,832 million in Q1 2026, attributed to preparations for the Rockville acquisition from MacroGenics. The net debt-to-equity ratio decreased to 71.3%, reflecting a five-quarter trend of debt reduction.

The CDMO segment emerged as a primary growth driver, boasting a record backlog of US$317 million and new contract wins totaling US$378.2 million.